| Literature DB >> 30267203 |
Adeline Blandinières1,2,3, Thomas Gille4, Jérémy Sadoine5, Ivan Bièche2,6, Lofti Slimani5, Blandine Dizier2,3, Pascale Gaussem1,2,3, Catherine Chaussain5, Carole Planes4, Peter Dorfmüller7, Dominique Israël-Biet2,3,8, David M Smadja9,10,11.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterized by fibroblast proliferation, extracellular matrix deposition, destruction of pulmonary alveolar architecture and vascular remodeling. Apart pirfenidone or nintendanib that only slow down the fibrotic process, there is no curative treatment other than lung transplantation. Because cell therapy approaches have been proposed in IPF, we hypothesized that injection of endothelial colony-forming cells (ECFCs), the vasculogenic subtype of endothelial progenitor cells, could modulate fibrosis in a Nude mouse model of bleomycin induced-pulmonary fibrosis. Mice were injected with ECFCs isolated from cord blood and from peripheral blood of adult IPF patients at two time-points: during the development of the fibrosis or once the fibrosis was constituted. We assessed morbidity, weight variation, collagen deposition, lung imaging by microCT, Fulton score and microvascular density. Neither ECFCs isolated from cord blood nor from IPF patients were able to modulate fibrosis or vascular density during fibrogenesis or when fibrosis was constituted. These findings indicate that human ECFCs do not promote an adaptive regenerative response in the lung upon fibrosis or angiogenic process in the setting of bleomycin-induced pulmonary fibrosis in Nude mice.Entities:
Keywords: Bleomycin; ECFC; Endothelial colony forming cells; Endothelial progenitor cells; Fibrosis; Lung
Mesh:
Substances:
Year: 2018 PMID: 30267203 DOI: 10.1007/s12015-018-9846-5
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 5.739